Table of Contents
- Effects of prescribed medical cannabis and alcohol on real-world driving performance (CAN-TRACK): a study protocol for a two-phase trial.
- FAQ
- FAQ
- Can patients safely drive after taking prescribed medical cannabis?
- What are the current legal restrictions for driving with medical cannabis in Australia?
- Which medical conditions will be studied in this driving safety research?
- How will researchers measure the actual impact of medical cannabis on driving ability?
- How might this research influence medical cannabis driving laws?
Effects of prescribed medical cannabis and alcohol on real-world driving performance (CAN-TRACK): a study protocol for a two-phase trial.
Australian researchers outline protocol for first real-world driving assessment of prescribed medical cannabis versus placebo in patients with chronic conditions.
This protocol represents the first structured attempt to measure real-world driving performance in medical cannabis patients using their actual prescriptions at therapeutic doses. The two-phase design combining patient and healthy volunteer cohorts could provide critical safety data that current laboratory studies cannot capture.
Current zero-tolerance THC driving laws may criminalize medical cannabis patients regardless of actual impairment, creating a significant gap between legal policy and clinical reality. Real-world driving data could inform evidence-based road safety regulations that distinguish between therapeutic use and recreational intoxication.
| Study Type | Study Protocol |
| Population | Phase 1: 72 patients with chronic pain, anxiety, or insomnia (24 per condition); Phase 2: 24 healthy participants |
| Intervention | Standard prescribed medical cannabis doses containing THC |
| Comparator | Placebo control in Phase 2; pre-dose baseline in Phase 1 |
| Primary Outcome | Real-world on-track driving performance measures |
| Key Finding | Protocol design described; no results reported |
| Journal | Trials |
| Year | 2024 |
While no results are available, this study design could generate the first robust evidence about whether prescribed medical cannabis doses actually impair driving performance in real-world conditions. The findings may be crucial for patient counseling about driving safety and informing regulatory policy.
This is a protocol paper with no actual results, outcomes, or safety data reported. The study has not yet demonstrated whether medical cannabis impairs driving performance or validated any specific THC thresholds for impairment.
On-track driving assessments may not fully capture real-world driving complexity, and the study population may not represent all medical cannabis patients. The relationship between measured driving performance and actual crash risk remains unclear, and individual responses to THC vary significantly.
This protocol addresses a critical knowledge gap in medical cannabis safety, but represents future research rather than current evidence. Clinicians should continue advising patients about driving risks while awaiting actual study results that could inform evidence-based recommendations.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
FAQ
Can patients safely drive after taking prescribed medical cannabis?
Currently, it’s unclear whether therapeutic doses of medical cannabis cause driving impairment, despite many products containing THC. This Australian study protocol aims to provide the first real-world evidence by testing actual driving performance in patients taking prescribed doses for chronic conditions.
What are the current legal restrictions for driving with medical cannabis in Australia?
Australian laws currently prohibit driving with any detectable amount of THC in the system, regardless of whether it’s prescribed medical cannabis. This zero-tolerance policy applies even to patients using legal medical cannabis prescriptions for chronic health conditions.
Which medical conditions will be studied in this driving safety research?
The study will examine patients with three common conditions treated with medical cannabis: chronic pain, anxiety, and insomnia. A total of 72 patients will participate, with 24 patients in each condition group undergoing repeated on-track driving assessments.
How will researchers measure the actual impact of medical cannabis on driving ability?
The study uses a two-phase approach: real patients will complete on-track driving tests before and after taking their prescribed cannabis dose, followed by a controlled study with healthy volunteers using placebo comparison. This design provides both real-world and controlled laboratory evidence.
How might this research influence medical cannabis driving laws?
This study aims to generate novel data specifically to inform road safety policy regarding prescribed medical cannabis use. The findings could potentially support evidence-based policy changes if therapeutic doses don’t significantly impair driving performance compared to current zero-tolerance approaches.
